[Platelet function tests: tailored antiplatelet therapy for vascular patients?]

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Pathology

Background:

• Antiplatelet therapy (APT) is crucial for preventing secondary cardiovascular events (CVE) post-revascularization.
• High on-treatment platelet reactivity (HTPR) signifies reduced APT effectiveness and elevates CVE risk.
• Platelet function tests (PFT) can identify HTPR, with light transmission aggregometry (LTA) as the gold standard.

Purpose of the Study:

• To evaluate the diagnostic role and clinical utility of PFTs in managing antiplatelet therapy.
• To determine if PFTs can optimize APT and reduce secondary CVE in patients undergoing endovascular procedures.

Main Methods:

• Review of current literature on PFTs and their correlation with clinical outcomes.
• Analysis of different PFT methodologies, including LTA, and their specific applications.
• Assessment of studies investigating the impact of PFT-guided therapy adjustments.

Main Results:

• PFTs can detect HTPR, a state associated with increased risk of CVE.
• The clinical benefit of routine PFT use to optimize APT remains inconclusive.
• Certain patient subgroups, like those with renal failure, may benefit from PFT consideration.

Conclusions:

• Routine use of PFTs for optimizing antiplatelet therapy is not currently indicated in clinical practice.
• PFTs may be considered for specific high-risk patient populations with thromboembolic disease.
• Further research is needed to establish clear guidelines for PFT implementation in APT management.